文献速递免疫规划卫生政策与健康促进

美国65岁及以上曾接种肺炎球菌疫苗成人使用PCV21的成本效果分析

A Cost-Effectiveness Analysis of PCV21 Use in Vaccine-Experienced Adults Aged ≥65 Years in the U.S.
PubMed 文献 · Am J Prev Med · 2026-02-06

本研究采用已发表的多队列马尔可夫模型,从社会视角评估65岁及以上曾接种肺炎球菌疫苗成人中PCV21相比PPSV23、PCV15和PCV20的终生临床与经济结局。结果显示,在PPSV23曾接种者中PCV21相比PCV15每获得一个QALY需2700美元,在PCV13和PCV15曾接种者中相比PPSV23分别需130700和173700美元,且相比PCV20在所有曾接种者中均节省成本。结论认为PCV21在广泛输入和情景下具有经济合理性。

要点

  • PCV21在PPSV23曾接种者中相比PCV15每QALY需2700美元。
  • PCV21在PCV13和PCV15曾接种者中相比PPSV23每QALY分别需130700和173700美元。
  • PCV21相比PCV20在所有疫苗曾接种成人中均节省成本。

核心结论

  • 在美国65岁及以上曾接种肺炎球菌疫苗成人中,接种一剂PCV21可在广泛输入和情景下保持经济合理性,并可能预防相当数量的肺炎球菌疾病病例和死亡。

研究设计与样本

  • 采用已发表的多队列马尔可夫模型,从社会视角估算每种接种策略的终生临床和经济结局。
  • 质量调整生命年(QALY)和成本(2023美元)按3%年贴现率贴现。
  • 研究对象为65岁及以上、5年前曾接种PPSV23或PCV13或2年前曾接种PCV15的成人。
  • 进行了敏感性分析和情景分析以识别 influential 变量。

主要发现

  • 在PCV13曾接种成人中,PCV21相比PPSV23每获得一个QALY需130700美元。
  • 在PCV15曾接种成人中,PCV21相比PPSV23每获得一个QALY需173700美元。
  • 在PPSV23曾接种成人中,PCV21相比PCV15每获得一个QALY需2700美元。
  • PCV21相比PCV20在所有疫苗曾接种成人中均节省成本。
  • 贴现率和疫苗效果是最具影响力的输入,概率敏感性分析中定量结果稳健。

关键数值与推荐

  • 在PPSV23、PCV13或PPSV23+PCV13曾接种成人中,当疫苗史延长至8年(而非5年)时,PCV21在多数比较中略更有利。

临床怎么用

  • 对于65岁及以上曾接种肺炎球菌疫苗的成人,PCV21相比PCV20可节省成本,相比PPSV23或PCV15需根据既往疫苗史评估增量成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the U.S., pneumococcal conjugate vaccine (PCV) with higher valency such as 21-valent pneumococcal conjugate vaccine (PCV21) is recommended for adults aged ≥65 years who have previously received pneumococcal vaccines (referred to as vaccine experienced). This study assessed the cost-effectiveness of PCV21 versus 23-valent pneumococcal polysaccharide vaccine (PPSV23), 15-valent pneumococcal conjugate vaccine (PCV15), and 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged ≥65 years who were previously vaccinated 5 years ago with PPSV23 or PCV13 or 2 years ago with PCV15. METHODS: A published multicohort Markov model was used to estimate the lifetime clinical and economic outcomes of each vaccination strategy from a societal perspective. Quality-adjusted life years and costs (in 2023 U.S. dollars) were discounted at a 3% annual rate. Sensitivity and scenario analyses were conducted to identify influential variables. RESULTS: Compared with PPSV23, PCV21 in PCV13-, and PCV15-experienced adults would cost $130,700 and $173,700 per quality-adjusted life year gained, respectively. Administering PCV21 in PPSV23-experienced adults would cost $2,700 per QALY gained compared with administering PCV15. PCV21 would be cost saving compared with PCV20 in all vaccine-experienced adults. Discount rates and vaccine effectiveness were the most influential inputs, and the quantitative results were robust in probabilistic sensitivity analyses. When vaccine history was extended to 8 (instead of 5) years for the PPSV23-, PCV13-, or PPSV23+PCV13-experienced adults , PCV21 were slightly more favorable in most comparisons. CONCLUSIONS: In the U.S., a dose of PCV21 in adults aged ≥65 years who have previously received a pneumococcal vaccine has the potential to prevent a considerable number of pneumococcal disease cases and deaths while remaining economically reasonable over a wide range of inputs and scenarios.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Yi Z, Owusu-Edusei K, Elbasha EH, et al. A Cost-Effectiveness Analysis of PCV21 Use in Vaccine-Experienced Adults Aged ≥65 Years in the U.S. Am J Prev Med. 2026. PMID: 41655653. doi:10.1016/j.amepre.2026.108303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。